233 filings
Page 4 of 12
8-K
br6o41q0tea2g1p0xv21
18 Mar 22
Departure of Directors or Certain Officers
9:01am
8-K
tlvaa1237f6
2 Feb 22
Termination of a Material Definitive Agreement
4:35pm
8-K
ipdrkqontvzuy
2 Sep 21
Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
4:05pm
EFFECT
05whglw8 4n
8 Jun 21
Notice of effectiveness
12:15am
8-K
9vcqzmq2uvyacv59
4 Jun 21
Departure of Directors or Certain Officers
4:05pm
CORRESP
3183 qz84gnpl
3 Jun 21
Correspondence with SEC
12:00am
UPLOAD
9coy5ap kp31g
3 Jun 21
Letter from SEC
12:00am
8-K
w5a7oqlkbs09f10tmr
10 May 21
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
4:06pm
S-8
bsb11bc6ya n94
8 Apr 21
Registration of securities for employees
4:06pm
8-K
8ououh7j0s
24 Mar 21
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
8:01am
8-K
esuqx7w7s t841yu4
10 Nov 20
Regulation FD Disclosure
4:07pm
8-K
1bre7
9 Nov 20
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
4:56pm
8-K
l1rl9b1nhgeo90f
29 Oct 20
Other Events
5:28pm